- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07950930
DAX-044 in Adults With Advanced Solid Tumours: a First-in-human Study of Safety, Dose and Early Anti-cancer Activity.
A Phase 1 First-in-human Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumour Activity of Intravenous DAX-044 in Adults With Advanced Solid Tumours.
This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety and tolerability of DAX-044 as monotherapy, and to determine its maximum tolerated dose, in adults with advanced solid tumours.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and anti-tumour activity of DAX-044, a targeted, potency-optimised interleukin-12 (IL-12) immunocytokine, as monotherapy in adults with advanced solid tumours.
Part 1 (dose escalation) will evaluate DAX-044 monotherapy across planned dose levels, using a Bayesian optimal interval (BOIN) design to determine the maximum tolerated dose (MTD). Participants with any of the eligible tumour types are enrolled together into dose-level cohorts. Each participant remains at their allocated dose level; escalation occurs between cohorts only. Additional participants may be enrolled into backfill cohorts at dose levels already cleared for safety.
Part 2 (dose expansion) will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts.
In both parts, DAX-044 is given by intravenous infusion on Day 1 of each 21-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent or sponsor termination, to a maximum of 24 months.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Iva Nikolic
- Telefonnummer: +61 3 9067 5625
- E-mail: clinops@audax.bio
Undersøgelse Kontakt Backup
- Navn: Joanne Yan
- Telefonnummer: +61 3 9067 5625
- E-mail: clinops@audax.bio
Studiesteder
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Linear Clinical Research Ltd
-
Kontakt:
- Desi du Plessis
- Telefonnummer: +61 8 63825100
- E-mail: actcstartup@linear.org.au
-
Ledende efterforsker:
- Timothy Guy Humphries
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Aged at least 18 years.
- Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer, gastric or gastro-oesophageal junction adenocarcinoma, squamous cell carcinoma of the head and neck, melanoma other than ocular or uveal, triple-negative breast cancer, castrate-resistant prostate cancer (CRPC), microsatellite stable colorectal cancer, pancreatic ductal adenocarcinoma, or epithelial ovarian cancer. Tumour-type-specific requirements for prior therapy also apply.
- Measurable disease by RECIST v 1.1, except CRPC, which may be measurable or non-measurable.
- At least 1 prior line of systemic standard-of-care therapy, with radiographic progression on or after the last line received. CRPC with non-measurable disease must instead show progression of PSA.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy greater than 3 months.
- Able to provide pre-treatment tumour tissue, either archival or as a fresh biopsy.
- Adequate organ function within 14 days before first dose, including absolute neutrophil count greater than or equal to 1.5 x 10^9/L, platelets greater than or equal to 100 x 10^9/L, haemoglobin greater than or equal to 9 g/dL, bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), transaminases less than or equal to 3 times the ULN (5 times the ULN if liver metastases are present), and creatinine clearance greater than or equal to 50 mL/min.
- Agreement to use contraception according to the protocol.
Exclusion Criteria:
- Pregnant, breast-feeding, or planning to become pregnant during the study.
- Any investigational medicinal product within 30 days, before Cycle 1 Day 1.
- Part 1 only: more than 4 prior lines of systemic chemotherapy in the advanced or metastatic setting. Part 2 instead applies tumour-type-specific requirements for prior lines of therapy.
- Uncontrolled brain metastases.
- Active or past autoimmune disease or immunodeficiency.
- Idiopathic pulmonary fibrosis, organising pneumonia, drug-induced or idiopathic pneumonia, or evidence of active pneumonia at screening.
- Severe cardiovascular disease within 6 months.
- Significant surgical procedures, other than diagnostic surgery, within 4 weeks before the start of study treatment, or expected to require significant surgery during the study period.
- Known human immunodeficiency virus infection or current active hepatitis B or hepatitis C. Participants with prior HBV infection with negative HBV DNA are eligible. Participants clinically cured of hepatitis C, at least 12 weeks after completing antiviral treatment, are eligible.
- History of life-threatening toxicity related to prior immune therapy, for example an inhibitor of PD-1 or PD-L1, an anti-CTLA-4 agent, or any other drug targeting T-cell activation or immune checkpoint pathways.
- A live virus vaccine within the 4 weeks before Cycle 1 Day 1, or plans to receive a live virus vaccine during the study.
- Corrected QT interval using Fridericia correction greater than 470 milliseconds.
- Prior treatment with DAX-044 or any interleukin-12-based agent.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part 1 - DAX-044 Monotherapy Dose Escalation
DAX-044 administered at ascending dose levels to participants with advanced solid tumours, to assess safety and tolerability and determine the maximum tolerated dose (MTD). Dose escalation follows a Bayesian optimal interval (BOIN) design. |
DAX-044 monotherapy |
|
Eksperimentel: Part 2 - DAX-044 Monotherapy Dose Expansion in Tumour-Specific Cohorts
Part 2 will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts. |
DAX-044 monotherapy |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v6.0
Tidsramme: Up to 24 months
|
Up to 24 months
|
|
Maximum Tolerated Dose (MTD) of DAX-044 Based on Dose-Limiting Toxicities (DLTs) (Part 1)
Tidsramme: Up to 24 months
|
Up to 24 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Serum Concentrations of DAX-044
Tidsramme: Up to 24 months
|
Up to 24 months
|
|
Maximum Observed Serum Concentration (Cmax) of DAX-044
Tidsramme: Up to 24 months
|
Up to 24 months
|
|
Time to Maximum Observed Serum Concentration (Tmax) of DAX-044
Tidsramme: Up to 24 months
|
Up to 24 months
|
|
Trough Serum Concentration (Ctrough) of DAX-044
Tidsramme: Up to 24 months
|
Up to 24 months
|
|
Area Under the Serum Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of DAX-044
Tidsramme: Up to 24 months
|
Up to 24 months
|
|
Terminal Half-Life (t1/2) of DAX-044
Tidsramme: Up to 24 months
|
Up to 24 months
|
|
Clearance (CL) of DAX-044
Tidsramme: Up to 24 months
|
Up to 24 months
|
|
Number of Participants With Anti-Drug Antibodies (ADA) to DAX-044
Tidsramme: Up to 24 months
|
Up to 24 months
|
|
Objective Response Rate (ORR) as Assessed by the Investigator per RECIST 1.1
Tidsramme: Up to 24 months
|
Up to 24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- DAX-044-2601
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .